TG Therapeutics, Inc. Common Stock Earnings Dividend

TG Therapeutics, Inc. Common Stock’s revenue jumped 70.27% since last year same period to $240.34Mn in the Q2 2026. On a quarterly growth basis, TG Therapeutics, Inc. Common Stock has generated 17.28% jump in its revenue since last 3-months.

TG Therapeutics, Inc. Common Stock’s net profit fell -72.4% since last year same period to $7.78Mn in the Q2 2026. On a quarterly growth basis, TG Therapeutics, Inc. Common Stock has generated -60.66% fall in its net profits since last 3-months.

TG Therapeutics, Inc. Common Stock’s net profit margin fell -83.79% since last year same period to 3.24% in the Q2 2026. On a quarterly growth basis, TG Therapeutics, Inc. Common Stock has generated -66.45% fall in its net profit margins since last 3-months.

TG Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.41 - a 46.43% jump from last quarter’s estimates.

TG Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.41.

TG Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -70.59% since last year same period to 0.05 in the Q2 2026. This indicates that the TG Therapeutics, Inc. Common Stock has generated -70.59% annual rate of fall in its earning per share (EPS) in the last 4 quarters.